Inventor · disambiguated record
So Wong
Also filed as: WONG SO · WONG SO CHUN
18 granted patents·5 pending applications·309 citations·filing 2002–2024
94Inventor score
Files withARROWHEAD PHARMACEUTICALS INC13MIRUS BIO CORP3ARROWHEAD MADISON INC2ROCHE MADISON INC2ROZEMA DAVID B2
Top patents by PatentIndex Score
23 records- 0198US8658211B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2012·Granted Feb 25, 2014·71 cites·23 claims
- 0298US8137695B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2007·Granted Mar 20, 2012·138 cites·27 claims
- 0394US11214801B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Jan 4, 2022·3 cites·30 claims
- 0494US6740336B2Process for generating multilayered particlesMIRUS CORP·Filed 2002·Granted May 25, 2004·42 cites·5 claims
- 0593US10597657B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Mar 24, 2020·6 cites·51 claims
- 0688US7045356B2Process for generating multilayered particlesMIRUS BIO CORP·Filed 2004·Granted May 16, 2006·19 cites·18 claims
- 0787US7094605B2Formation of polyampholytes in the presence of a polyionMIRUS BIO CORP·Filed 2005·Granted Aug 22, 2006·6 cites·19 claims
- 0886US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 0986US9976141B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD MADISON INC·Filed 2016·Granted May 22, 2018·5 cites·32 claims
- 1085US12365899B2RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jul 22, 2025·0 cites·22 claims
- 1185US9487556B2Polyconjugates for delivery of RNAi triggers to tumor cells in vivoARROWHEAD MADISON INC·Filed 2014·Granted Nov 8, 2016·6 cites·18 claims
- 1283US10995335B2RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 4, 2021·3 cites·19 claims
- 1377US7071163B2Compounds for targeting hepatocytes in vivoMIRUS BIO CORP·Filed 2003·Granted Jul 4, 2006·7 cites·20 claims
- 1477US2022064646A1RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3)ARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1576US7470539B2Formation of polyampholytes in the presence of a polyionROCHE MADISON INC·Filed 2005·Granted Dec 30, 2008·1 cites·17 claims
- 1674US11840688B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 1768US12503696B2RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2024·Granted Dec 23, 2025·0 cites·16 claims
- 1863US7501394B2Compounds for targeting hepatocytesROCHE MADISON INC·Filed 2006·Granted Mar 10, 2009·0 cites·19 claims
- 1961US2021238602A1RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of UseARROWHEAD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2058US2022152079A1Methods For The Treatment Of APOC3-Related Diseases And DisordersARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2157US2019062748A1Polyconjugates for Delivery of RNAi triggers to Tumor Cells In VivoARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2251US12221610B2RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and methods of useARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 11, 2025·0 cites·20 claims
- 2351US2017022497A1Polyconjugates for Delivery of RNAi triggers to Tumor Cells In VivoARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →